Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04537728
Other study ID # 2019P003657
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date December 31, 2021

Study information

Verified date August 2022
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this trial is to demonstrate early proof-of-concept for My Healthy Brain, an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of cognitive decline. The investigators will explore the feasibility, acceptability, and effect sizes of improvement in primary lifestyle outcomes as well as secondary outcomes of self-determination and subjective well-being.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date December 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age = 60 years - English fluency/literacy - =1 modifiable brain disease risk factor (outlined by JAMA) - Bluetooth 4.0 enabled smartphone Exclusion Criteria: - Diagnosis of dementia; Montreal Cognitive Assessment < 18 - Serious medical illness expected to worsen in next 6 months - Current suicidal ideation - Substance abuse - Untreated serious mental health conditions - Current use of digital monitoring device (eg. Fitbit) - Mindfulness practice (> 45 minutes/week) in the last three months

Study Design


Intervention

Behavioral:
My Healthy Brain Version 2
multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors

Locations

Country Name City State
United States Massachusetts General Hospital Cancer Center Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Massachusetts General Hospital Brigham and Women's Hospital, Harvard Medical School (HMS and HSDM)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Credibility and Expectancy Questionnaire (CEQ) percent of participants that score beyond scale midpoint Baseline (0 Weeks)
Primary Client Satisfaction Questionnaire (CSQ-3) Items are summed to generate a total score; scores range from 3 to 12, with higher values indicating higher satisfaction. Baseline (0 Weeks), Post-Test (8 Weeks)
Primary Recruitment Feasibility percent of referred patients meeting criteria to participate Baseline (0 Weeks)
Primary Program Acceptability percent of participants completing at least 6 sessions Baseline (0 Weeks), Post-Test (8 Weeks)
Primary Treatment Fidelity percent of sessions rated as 100% adherent Baseline (0 Weeks), Post-Test (8 Weeks)
Primary Assessment Feasibility percent of post-questionnaires completed Baseline (0 Weeks), Post-Test (8 Weeks)
Primary Adherence to Actigraph percent of participants wearing Actiwatch = 5 days per week Baseline (0 Weeks), Post-Test (8 Weeks)
Primary Adherence to Lifestyle Behaviors percent of participants completing weekly homework Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Change in Healthy Aging change from baseline to post test; measured by Brain Health Behaviors Checklist Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Mindfulness: Cognitive and Affective Mindfulness Scale change from baseline to post test; Scores range from 12-48, with higher values reflecting greater mindfulness qualities. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Mindfulness: Homework log change from baseline to post test; measured by self-reported number of minutes practiced Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Mindfulness: Five-Facet Mindfulness Questionnaire change from baseline to post test; Scores range from 15-75, with higher scores indicating greater mindfulness. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Sleep: Pittsburgh Sleep Quality Index change from baseline to post test;Total scores range from 0 to 21, with higher scores indicating greater sleep disturbance. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Sleep: Jenkins Sleep Questionnaire change from baseline to post test; scores range from 0-20, with higher scores indicating greater sleep disruption. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Sleep: Actigraph measures of sleep change from baseline to post test Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Physical Activity: PROMIS Physical Function change from baseline to post test; scores range from 4-16, with higher scores signifying greater physical function. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Physical Activity: Godin Leisure Time Exercise Questionnaire change from baseline to post test; scores range from 0 to no upper limit, with higher scores indicating greater activity level. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Physical Activity: Rapid Assessment of Physical Activity change from baseline to post test; the highest score with an affirmative response is used for scoring, with higher scores indicating greater physical activity. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Physical Activity: Actigraph measures of activity change from baseline to post test Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Nutrition: Mediterranean Eating Pattern for Americans Screener change from baseline to post test; scores range from 0-16, with higher scores indicating a greater adherence to the Mediterranean diet. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Nutrition: MIND Diet Adherence Checklist change from baseline to post test; scores range greater than or equal to 0, with higher scores indicating creater adherence to MIND diet. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Medication and Substance Use: Morisky Medication Adherence Scale change from baseline to post test; scores range from 0-4 with higher scores indicating greater adherence to medication regiment. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Medication and Substance Use: Alcohol Use Disorders Identification Test-Consumption change from baseline to post test; Scores range from 0-12, with higher scores indicating more hazardous drinking. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Medication and Substance Use: Fagerstrom Test for Nicotine Depedence change from baseline to post test; scores range from 0-10, with higher total scores indicating greater physical dependence on nicotine. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Stress and Emotional Functioning: Perceived Stress Scale change from baseline to post test; scores range from 0-40, with higher scores indicating greater perceived stress. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Stress and Emotional Functioning: PROMIS Depression change from baseline to post test; scores range from 8-40, with higher scores indicating greater depression. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Stress and Emotional Functioning: PROMIS Anxiety change from baseline to post test; scores range from 8-40, with higher scores indicating greater anxiety. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Stress and Emotional Functioning: Heart Rate Variability (Actigraphy) change from baseline to post test Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Social Functioning: PROMIS Social Isolation change from baseline to post test; scores range from 6-30, with higher scores indicating greater social isolation. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Social Functioning: PROMIS Emotional Support change from baseline to post test; scores range from 4-16, with higher scores indicating lower emotional support. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Social Functioning: UCLA Loneliness Scale change from baseline to post test; scores range from 0-24, with higher scores indicating stronger perceptions of loneliness and social isolation. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Cognitive Functioning: Everyday Cognition Scale change from baseline to post test; scores range from 12-60, with higher scores indicating worse cognitive ability to perform everyday tasks. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Cognitive Functioning: PROMIS Cognition change from baseline to post test; scores range from 8-40, with higher scores indicating greater patient-perceived cognitive deficits. Baseline (0 Weeks), Post-Test (8 Weeks)
Secondary Cognitive Functioning: Montreal Cognitive Assessment change from baseline to post test; scores range from 0-30, with higher scores representing greater global cognitive capacity. Baseline (0 Weeks), Post-Test (8 Weeks)
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A